[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630420":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":22,"locations":31,"responsibleParty":48,"collaborators":52,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":10,"eligibilityCriteria":61,"healthyVolunteers":58,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":10,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":10,"overallStatus":73,"whyStopped":10,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"University of Arizona","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"Feasibility Group",null,"The feasibility group will consist of 10 participants with Group 1 Pulmonary Hypertension (idiopathic, drug induced, or hereditary) to be enrolled in the first phase of the study.",{"label":13,"type":10,"description":14,"interventionNames":10},"Real World Cohort - Treatment Naïve Cohort","This cohort will consist of 10 participants with Group 1 Pulmonary Hypertension (all types), treatment naïve, to be enrolled in the second phase of the study.",{"label":16,"type":10,"description":17,"interventionNames":10},"Real World Cohort - Prevalent Cohort","This cohort will consist of 10 participants with Group 1 Pulmonary Hypertension (all types) to be enrolled in the second phase of the study.",[19],{"name":20,"affiliation":5,"role":21},"Franz Rischard, MD","PRINCIPAL_INVESTIGATOR",[23,28],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"The clinical and translational sciences research center","CONTACT","(520) 626-8000","esmeralda97h@arizona.edu",{"name":29,"role":25,"phone":30,"phoneExt":10,"email":27},"Study Coordinator","(520) 626-4804",[32],{"facility":33,"status":10,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"The Clinical and Translational Sciences Research Center","Tucson","Arizona","85724","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-110.92648,32.22174,{"lat":43,"lon":42},[46],{"name":47,"role":25,"phone":30,"phoneExt":10,"email":27},"Esme Study Coordinator",{"type":49,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Franz Rischard, DO","DO",[53],{"name":54,"class":55},"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA","INDUSTRY","100630420","reverse-remodeling-of-the-pulmonary-vasculature-a-longitudinal-investigational-study-of-the-effects-of-sotatercept-100630420",false,"NCT07487441","Reverse Remodeling of the Pulmonary Vasculature: a Longitudinal, Investigational Study of the Effects of Sotatercept.","Inclusion Criteria - Feasibility Group:\n\n* Group 1 Pulmonary Hypertension (G1PH)-must be idiopathic, drug induced, or hereditary (D\u002FH\u002FI)\n* Age \\\u003C 65 years at time of diagnosis\n* Must be 18 years of age or older\n\nInclusion Criteria - \"Real-world\" treatment naïve cohort:\n\n* Group 1 Pulmonary Hypertension (G1PH)-all types\n* Must be treatment naïve\n* Must be 18 years of age or older\n\nInclusion Criteria - \"Real-world\" prevalent cohort:\n\n* Group 1 Pulmonary Hypertension (G1PH)-all types\n* Must be 18 years of age or older\n\nExclusion Criteria:\n\n* Contraindication to right heart catheterization (per PI)\n* Prior exposure to sotatercept\n* Hemoglobin \\> 18 g\u002FdL at screening\n* Estimated GFR \\\u003C 30 mL\u002Fmin at screening\n* Platelet count \\\u003C30 at screening\n* Positive pregnancy test","ALL","18 Years","65 Years",{"count":66,"type":67},30,"ESTIMATED","OBSERVATIONAL","The goal of this study is to learn more about how sotatercept works and if it helps the lung arteries become healthier. Sotatercept will be associated with the following:\n\n1. Improvement in capillary blush, reduce the tapering and tortuosity of affected vessels on pulmonary wedge angiography and decreased wall thickness on intravascular ultrasound in previously affected areas.\n2. Improvement in previously poorly or non-perfused areas rather than increased perfusion to previously perfused areas.\n3. No changes in baseline ventilation and improvement and ventilation\u002Fperfusion matching.",[71,72],"Pulmonary Arterial Hypertension (PAH)","Pulmonary Hypertension","NOT_YET_RECRUITING","2026-03-17",{"date":76,"type":77},"2026-03-23","ACTUAL",{"date":79,"type":67},"2026-03-15",{"date":81,"type":67},"2028-06-15",{"name":50,"class":6},1]